Statements
NHS Clinical Commissioners co-ordinate support from CCGs to review use of Avastin to treat wet AMD
College Statement In response to the public letters sent by the NHS Clinical Commissioners to Secretary of State for Health, cc. Chair of NICE; Simon Stevens at NHS England; and the Chair of the GMC and signed by the Clinical Chair / Lead Clinician of 120 CCGs regarding the use of Avastin to treat wet AMD. The Royal
Cataract Provision – RCOphth statement
The Royal College of Ophthalmologists (RCOphth) sets the standards for all eye healthcare, including eye surgery, and it is very concerned about the reports from Musgrove Park Hospital. Cataract surgery is a highly effective, life-enhancing procedure which, if performed according to RCOphth standards in a safe environment, carries very little risk. We recommend that surgical
Use of Avastin (bevacizumab) in age related macular degeneration
Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no
President’s foreword for RNIB Report ‘Real Patients Coming to Real Harm’ Wales
A substantial part of the workload of ophthalmology services is the care of long term conditions such as glaucoma, diabetic retinopathy and age-related macular degeneration. These conditions all become increasingly common with advancing age and all require timely recognition and treatment in order to avoid preventable sight loss. Unfortunately, clinical services for these long-term conditions
French health regulator reviews use of Avastin to treat AMD
College Statement The RCOphth notes with interest the move by the French health regulator, French National Agency for Medicines and Health Products Safety (ANSM), in asking Roche to provide information on the safety and efficiency of the off-label use of bevacizumab (Avastin) to treat wet age-related macular degeneration (AMD). Ranibizumab (Lucentis), which is licensed as